Compass Therapeutics, Inc. financial data

Symbol
CMPX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
80 Guest Street, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Olivia Ventures, Inc. (to 6/8/2020)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.09K % +43.9%
Debt-to-equity 5.22 % -37.3%
Return On Equity -30.9 % -16%
Return On Assets -29.4 % -19.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 138M shares +7.95%
Common Stock, Shares, Outstanding 138M shares +8.01%
Entity Public Float 283M USD +53.8%
Common Stock, Value, Issued 14K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 138M shares +8.57%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 14M USD +17.3%
Operating Income (Loss) -55.1M USD -13.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -47.2M USD -10.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -47.2M USD -10.7%
Earnings Per Share, Basic -0.36 USD/shares +2.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.4M USD +0.65%
Marketable Securities, Current 127M USD -15.2%
Cash, Cash Equivalents, and Short-term Investments 175M USD
Assets, Current 154M USD -12.4%
Property, Plant and Equipment, Net 592K USD -50.8%
Operating Lease, Right-of-Use Asset 1.15M USD -51.7%
Other Assets, Noncurrent 320K USD 0%
Assets 156M USD -13.2%
Accounts Payable, Current 1.19M USD +64.6%
Accrued Liabilities, Current 7.23M USD -7.67%
Liabilities, Current 9.51M USD -1.97%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 9.51M USD -12.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -91K USD +82.1%
Retained Earnings (Accumulated Deficit) -339M USD -16.2%
Stockholders' Equity Attributable to Parent 146M USD -13.2%
Liabilities and Equity 156M USD -13.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.9M USD -13.6%
Net Cash Provided by (Used in) Financing Activities 17.4M USD +42420%
Net Cash Provided by (Used in) Investing Activities -4.1M USD -196%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 138M shares +7.95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -554K USD +93%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Gross 44.3M USD +53.6%
Operating Lease, Liability 1.09M USD -53.6%
Depreciation 200K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -46.8M USD -9.72%
Lessee, Operating Lease, Liability, to be Paid 1.12M USD -55%
Property, Plant and Equipment, Gross 7.17M USD +0.27%
Operating Lease, Liability, Current 1.09M USD -5.14%
Lessee, Operating Lease, Liability, to be Paid, Year Two 543K USD -60.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 543K USD -60.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 30K USD -78.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 543K USD -60.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.3M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 485K USD -40%
Share-based Payment Arrangement, Expense 7.35M USD +41.1%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%